Abstract
Vandetanib inhibits vascular endothelial growth factor receptor (VEGFR) 2 tyrosine kinase activity in endothelial cells and, to a lesser degree, endothelial growth factor receptor (EGFR) tyrosine kinase activity in tumor cells. Vandetanib has been developed for the treatment of non–small-cell lung cancer (NSCLC), either alone or in combination with second-line chemotherapy. We describe a case of interstitial lung disease (ILD) in a patient who received vandetanib in a randomized, controlled, double-blind trial by comparing a pemetrexed combination with either vandetanib or placebo.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
